Browse by author
Lookup NU author(s): Professor Richard McQuade
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Recent studies indicate that 5-HT1A receptor agonists stimulate noradrenaline release in the brain. Here we investigate the mechanism underlying the increase in extracellular noradrenaline induced by (±)-MDL 73005EF, a weak 5-HT1A receptor agonist. Extracellular noradrenaline was measured in the hippocampus of the awake rat using microdialysis. (±)-MDL 73005EF (0.1, 1 and 5 mg/kg s.c.) caused a dose-related increase in noradrenaline. The active S(−)- enantiomer of MDL 73005EF (1 mg/kg s.c.) also increased noradrenaline whereas the inactive R(+)- enantiomer (1 mg/kg s.c.) did not. Measurements of extracellular 5-HT in hippocampus of anaesthetised rats confirmed that the 5-HT1A receptor agonist action of (±)-MDL 73005EF resides in the S(−)- enantiomer. Thus, S(−)-MDL 73005EF (0.3 and 1 mg/kg s.c.) markedly decreased 5-HT, whereas R(+)-MDL 73005EF (1 mg/kg s.c.) did not. The noradrenaline response to (±)-MDL 73005EF (1 mg/kg s.c.) was significantly blocked by the selective 5-HT1A receptor antagonist, WAY 100635 (1 but not 0.3 mg/kg s.c). The noradrenaline response to (±)-MDL 73005EF (1 mg/kg s.c.) was not modified by pretreatment with the 5-HT synthesis inhibitor p-chlorophenylalanine. Intra-hippocampal application of (±)-MDL 73005EF (10 μM in perfusion medium) did not increase noradrenaline. Although (±)-MDL 73005EF has moderate affinity for dopamine D2 binding sites, the dopamine D2 receptor antagonist, remoxipride (1 mg/kg s.c.) did not increase noradrenaline. In conclusion, our data suggest that (±)-MDL 73005EF increases noradrenaline release in rat hippocampus through activation of 5HT1A receptors that appear to be located postsynaptically. These data are discussed in relation to the antidepressant/anxiolytic effects of 5-HT1A agonists.
Author(s): McQuade R; Hajos-Korcsok E; Sharp T
Publication type: Article
Publication status: Published
Journal: Neuropharmacology
Year: 1999
Volume: 38
Issue: 2
Pages: 299-306
Print publication date: 01/02/1999
ISSN (print): 0028-3908
ISSN (electronic): 1873-7064
Publisher: Pergamon
URL: http://dx.doi.org/10.1016/S0028-3908(98)00175-0
DOI: 10.1016/S0028-3908(98)00175-0
Altmetrics provided by Altmetric